Ruibo Bio-B (06938) submits phase I clinical trial application for RBD3133 injection to treat overweight and obesity

Zhitongcaijing · 1d ago

Zhitong Finance App News, Ruibo Bio-B (06938) announced that it has submitted a phase I clinical trial application for the company's siRNA product RBD3133 injection targeting INHBE in the European Union to treat overweight and obesity.

RBD3133 injection is designed to selectively silence INHBE (a gene encoding activin E protein). Human genetics studies have shown that individuals with natural INHBE functional loss variants have healthier fat distribution, improved metabolic characteristics, and lower estimated risk of coronary heart disease and type 2 diabetes. These findings support INHBE as a promising therapeutic target for the treatment of obesity and related metabolic diseases.

This phase I study was a randomized, placebo-controlled trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous injections of RBD3133 in overweight or obese subjects. This trial will provide the first evaluation of RBD3133 in humans and will lay the foundation for further clinical development.

RBD3133 is a key milestone in the company's siRNA product development portfolio in the field of cardiovascular and metabolic diseases, and is expected to become a cornerstone drug for the treatment of cardiovascular and metabolic diseases related to weight loss. As the company's first drug candidate in the field of obesity treatment, RBD3133 reflects the company's strategic focus on developing innovative drugs for a large group of patients with significant unmet medical needs.